Sagimet Biosciences Inc. (SGMT)
2025-06-30 | 2024-09-30 | |||
|---|---|---|---|---|
| Net unrealized loss on marketable securities | -45 | 464 | ||
| Interest income and other, net | 1,539 | 2,283 | ||
| Total other income | 1,539 | 2,283 | ||
| Research and development expenses | 7,248 | 12,653 | ||
| General and administrative expenses | 4,677 | 4,249 | ||
| Total operating expenses | 11,925 | 16,902 | ||
| Loss from operations | -11,925 | -16,902 | ||
| Net loss | -10,386 | -14,619 | ||
| Total comprehensive loss | -10,431 | -14,155 | ||
| Earnings per share, basic | -0.32 | -0.45 | ||
| Earnings per share, diluted | -0.32 | -0.45 | ||
| Weighted average number of shares outstanding, basic | 32,195,366 | 32,143,336 | ||
| Weighted average number of shares outstanding, diluted | 32,195,366 | 32,143,336 | ||